Projekt współfinansowany ze środków Unii Europejskiego w ramach Europejskiego Funduszu Społecznego


Opcje terapeutyczne w raku wątrobowokomórkowym

Rak wątrobowokomórkowy

Rak wątrobowokomórkowy ? rozpoznanie i leczenie

Marskość wątroby związana z HBV i HCV

Przeszczepienie wątroby u chorych z rakiem wątrobowokomórkowym

Aflatoxins Interaction BC


HCC Cancer LettEd

HCC Case Report

HCC epid Prevention

HCC genotyp HBV

HCC other BC

HCC ther1

HCC ther2

HCC recommendation

Carcinoma Hepatocelulare HCC

Hepatocellular carcinoma, imaging methods



1. Cieszanowski A., Szeszkowski W., Gołębiowski M., Bielecki D.K., Grodzicki M., Pruszyński B.: ?Discrimination of benign from malignant hepatic lesions based on their T2 relaxation times calculated from moderately T2-weighted turbo SE sequence? Eur Radiol 2002, 12, 2273-2279

2. Cieszanowski A., Gołębiowski M., Szwejda E., Szeszkowski W., Jaworski M.: ?Ogniskowy przerost guzkowy w badaniu MR: ocena przydatności obrazów T1 i T2 zależnych oraz wzmocnienia kontrastowego? Pol J Radiol 2004, 69, 69-74

3. Cieszanowski A., Gołębiowski M., Maj E., Pruszyński B., Grodzicki M., Jaworski M., Rowiński O., Krawczyk M.: ?Ocena przydatności hepatotropowego środka kontrastowego Teslascan (Mn-DPDP) w wykrywaniu zmian ogniskowych w wątrobie? Pol.J.Radiol. 2006, 71 (2), 62-69

4. Cieszanowski A., Palczewski P.: MR imaging ensures quality in focal liver lesions. Diagnostic Imaging Europe 2006, (7-8), 29-34.

5. Cieszanowski A., Szeszkowski W., Gołębiowski M., Grodzicki M., Maj E., Palczewski P., Krawczyk M., Rowiński O.: ?Różnicowanie zmian ogniskowych w wątrobie w badaniu MR za pomocą skojarzonej analizy ilościowo-jakościowej? Pol J Radiol 2007, 72 (1), 44-50.

PIŚMIENNICTWO (do wyboru):

1. Baron R.L., Oliver J.H., Dodd G.D. III et al.: Hepatocellular carcinoma: evaluation with biphasic contrast enhanced helical CT. Radiology 1996; 199: 505-11.

2. Bartolozzi C. Donati F. Cioni D. et al.: MnDPDP-enhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis. Eur.Radiol.2000; 10:1697-702.

3. Bipat S., Leeuwen M.S., Comans E.F. et al.: Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta analysis. Radiology 2005; 237: 123-31.

4. Braga H.J., Choti M.A., Lee V.S. et al.: Liver lesions: manganese-enhanced MR and dual-phase helical CT for preoperative detection and characterization comparison with receiver operating characteristic analysis. Radiology 2002; 223: 525-31.

5. Brancatelli G, Federle MP, Grazioli L et al.: Focal nodular hyperplasia: CT findings with emphasis on multiphasic helical CT in 78 patients. Radiology, 2001; 219: 61-68

6. Foley W.D., Mallisee T.A., Hohenwalter M.D.: Multiphase hepatic CT with a multirow detector CT scanner. AJR 2000; 175: 679-85.

7. Fujita T., Ito K., Honjo K. et al.: Detection of hepatocellular carcinoma: comparison of T2-weighted breath-hold Fast spin-echo sequences and high-resolution dynamic MR imaging with a phased-array body coil. J. Magn. Reson. Imaging 1999; 9: 274-9.

8. Fulcher A.S., Turner M.A., Capps G.W.: MR cholangiography: technical advances and clinical applications. Radiographics 1999; 19: 25-41.

9. Grazioli L., Morana G., Kirchin M.A., Schneider G.: Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimaglumine-enhanced MR imaging: prospective study. Radiology 2005; 236: 166-77.

10. Helmberger T., Semelka R.C.: New contrast agents for imaging the liver. MRI Clin. N. Amer. 2001; 9: 745-66.

11. Horton K.M., Bluemke D.A., Hruban R.H. et al.: CT and MR imaging of benign hepatic and biliary tumors. Radiographics, 1999; 19: 431-451

12. Hussain S.M., Semelka R.C., Mitchell D.G.: MR Imaging of hepatocellular carcinoma. MRI Clin.N.Amer. 2002; 10: 31-52.

13. Ji H., McTavish J., Mortele K. et al.: Hepatic imaging with multidetector CT. Radiographics 2001; 21: S71-S80.

14. Katsuyoshi I., Mitchell D.G., Outwater E.K. et al.: Hepatic lesions: discrimination of nonsolid, benign lesions from solid, malignant lesions with heavily T2-weighted fast spin-echo MR imaging. Radiology 1997, 204: 729-737

15. Kehagias D, Moulopoulos L, Antoniou A et al: Focal nodular hyprerplasia: imaging findings. Eur. Radiol. 2001; 11: 202-212

16. Kinkel K., Lu Y., Both M. et al.: Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002; 224: 748-56.

17. Kwak H.S., Lee J.M., Kim C.S.: Preoperative detection of hepatocellular carcinoma: comparison of combined contrast-enhanced MR imaging and combined CT during arterial portography and CT hepatic arteriography. Eur. Radiol. 2004; 14: 447-57.

18. Laghi A., Iannaccone R., Rossi P. Et al.: Hepatocellular carcinoma: detection with triple-phase multi-detector row helical CT in patients with chronic hepatitis. Radiology 2003; 226: 543-9.

19. Lee W.J., Lim H.K., Jang K.M. et al.: Radiologic spectrum of cholangiocarcinoma: emphasis on unusual manifestations and differential diagnoses. Radiographics 2001; 21: S97-S116.

20. Lopera J.E., Soto J.A., Munera F. et al.: Malignant hilar and perihilar biliary obstruction: use of MR cholangiography to define the extent of biliary ductal involvement and plan percutaneous interventions. Radiology 2001; 220: 90-96.

21. Low R.N.: MR imaging of the liver using gadolinium chelates. MRI Clin.N.Amer. 2001; 9: 717-43.

22. Mathieu D., Vilgrain V., Mahfouz A.E. et al.: Benign liver tumors. MRI Clin. N. Amer. 1997; 5: 255-88.

23. Menu Y., Vilgrain V., Terris B.: Malignant liver tumors. Eur Radiol, 2000; 10 (suppl. 2) S 185-94.

24. Mori K., Yoshioka H., Takahashi N. et al.: Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late and whole tripple arterial phase imaging. Am J Roentgenol 2005; 184: 63-9.

25. Morrin M.M., Rofsky N.M.: Techniques for liver MR imaging. MRI Clin. N. Amer. 2001; 9: 675-96.

26. Motohara T. Semelka R.C., Nagase L.: MR imaging of benign hepatic tumors. MRI Clin. N.Amer. 2002; 10: 1-14.

27. Oudkerk M., Torres C.G., Song B. et al.: Charactarization of liver lesions with mangafidipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase CT. Radiology 2002; 223: 517-24.

28. Pauleit D., Textor J., Bachmann R.: Hepatocellular carcinoma: detection with gagdolinium- and ferumoxides-enhanced MR imaging of the liver. Radiology 2002; 222: 73-80.

29. Pedro M.S., Semelka R.C., Braga L.: MR imaging of hepatic metastases. MRI Clin.N.Amer 2002; 10; 15-29.

30. Reimer P., Schneider G., Schima W.: Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur.Radiol. 2004; 14: 559-578.

31. Ros P.R.: Benign liver tumors. Eur Radiol, 2000; 10 (suppl. 2): S 175-84

32. Sahani D.V., Kalva S.P., Fishman A.J. et al.: Detection of liver meatstases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. Am J Radiol 2005; 185: 239-46.

33. Savellano D.H., Kostler H., BausS. Et al.: Assessment of sequential enhancement patterns of focal nodular hyperplasia and hepatocellular carcinoma on mangafodipir trisodium enhanced MR inaging. Invest Radiol 2004; 39: 305-12.

34. Semelka R.C., Cance W.G., Marcos H.B., Mauro M.A.: Liver metastases: comparison of current MR techniques and spiral CT during arterial portography for detection of 20 surgically staged cases. Radiology 1999; 213: 86-91.

35. Semelka R.C., Sofka C.M.: Hepatic Hemangiomas. MRI Clin N Amer, 1997; 5: 241-253

36. Soto J.A., Alvarez O., Lopera J.E. et al.: Biliary obstruction: findings at MR cholangiography and cross-sectional MR imaging. Radiographics 2000; 20: 353-66.

37. Valls C. Andia E., Sanchez A. et al.: Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT. Radiology 2001; 218: 55-60.

38. Ward J., Guthrie J.A., Scott D.J. et al.: Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 2000; 216: 154-162.

39. Ward J., Robinson P.J.: Combined use of MR contrast agents for evaluating liver disease. MRI Clin. N. Amer. 2001; 9: 767-783.

40. Yang M., Martin D.R., Karabulut N., Frick M.P. Comparison of MR and PET imaging for the evaluation of liver metastases. J. Magn.Res.Imaging 2003; 17: 343-9.